Baidu
map

Nature Communications:监测肿瘤状态的特殊基因

2015-02-05 佚名 生物谷

近日,刊登在国际杂志Nature Communications上的一篇研究论文中,来自西奈山医疗中心(Mount Sinai Medical Center)的研究人员通过研究发现两种癌症药物可以开启特殊基因的表达,而这种特殊基因则可以告知肿瘤细胞使其处于休眠状态。 文章中研究者表示,当名为NR2F1的基因开启后其就会重编程肿瘤细胞使其处于休眠状态;而当该基因的表达关闭后肿瘤细胞就会开始分裂并且发

近日,刊登在国际杂志Nature Communications上的一篇研究论文中,来自西奈山医疗中心(Mount Sinai Medical Center)的研究人员通过研究发现两种癌症药物可以开启特殊基因的表达,而这种特殊基因则可以告知肿瘤细胞使其处于休眠状态。

文章中研究者表示,当名为NR2F1的基因开启后其就会重编程肿瘤细胞使其处于休眠状态;而当该基因的表达关闭后肿瘤细胞就会开始分裂并且发生异常生长,从而潜在地使休眠中的细胞迅速生长成为肿瘤,并且发生全身性的转移。研究者表示,将抗癌药物氮杂胞苷和类维生素A进行结合就可以明显增加肿瘤细胞中活性NR2F1的水平。

NR2F1作为肿瘤细胞生长的主要调节基因,其影响着决定细胞是否处于休眠的许多基因的表达;本文研究显示,基因NR2F1在人类胚胎干细胞中发挥着长期的控制作用,在干细胞中其可以指挥细胞停止生长并且变成对生命活动重要的细胞,而NR2F1的这种功能也使其对肿瘤细胞可以施加较长的控制效应,当癌细胞从原发性位点增殖扩散后NR2F1就会促进癌细胞保持休眠状态。

Aguirre-Ghiso教授说道,我们的研究揭示了为何有些肿瘤细胞在扩散到全身后依然会数年保持休眠状态,而为何有些肿瘤细胞却会引发严重的疾病。药物氮杂胞苷和类维生素A可以抑制肿瘤细胞发生快速增殖,从而恢复正常细胞的功能,而一些活性的肿瘤则会抑制关闭肿瘤生长的基因的表达;如今研究人员已经拥有大量的证据可以证明已知抗癌药物的结合具有明显潜在的抗癌效应。

原始出处

Sosa MS1, Parikh F2, Maia AG3, Estrada Y1, Bosch A1, Bragado P1, Ekpin E1, George A1, Zheng Y4, Lam HM5, Morrissey C5, Chung CY3, Farias EF6, Bernstein E7, Aguirre-Ghiso JA8.NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes.Nat Commun. 2015 Jan 30

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2086763, encodeId=655b2086e63ee, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Feb 25 06:17:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880487, encodeId=0fec188048eb0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Dec 24 13:17:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15928, encodeId=b233159288c, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=207, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:49:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573388, encodeId=532b15e338886, content=<a href='/topic/show?id=28f4125430b' target=_blank style='color:#2F92EE;'>#Nature Communications#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12543, encryptionId=28f4125430b, topicName=Nature Communications)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bea15872676, createdName=qindq, createdTime=Sat Feb 07 00:17:00 CST 2015, time=2015-02-07, status=1, ipAttribution=)]
    2015-02-25 liuli5079
  2. [GetPortalCommentsPageByObjectIdResponse(id=2086763, encodeId=655b2086e63ee, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Feb 25 06:17:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880487, encodeId=0fec188048eb0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Dec 24 13:17:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15928, encodeId=b233159288c, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=207, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:49:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573388, encodeId=532b15e338886, content=<a href='/topic/show?id=28f4125430b' target=_blank style='color:#2F92EE;'>#Nature Communications#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12543, encryptionId=28f4125430b, topicName=Nature Communications)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bea15872676, createdName=qindq, createdTime=Sat Feb 07 00:17:00 CST 2015, time=2015-02-07, status=1, ipAttribution=)]
    2015-12-24 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=2086763, encodeId=655b2086e63ee, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Feb 25 06:17:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880487, encodeId=0fec188048eb0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Dec 24 13:17:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15928, encodeId=b233159288c, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=207, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:49:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573388, encodeId=532b15e338886, content=<a href='/topic/show?id=28f4125430b' target=_blank style='color:#2F92EE;'>#Nature Communications#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12543, encryptionId=28f4125430b, topicName=Nature Communications)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bea15872676, createdName=qindq, createdTime=Sat Feb 07 00:17:00 CST 2015, time=2015-02-07, status=1, ipAttribution=)]
    2015-02-16 windmilL1989

    已阅

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2086763, encodeId=655b2086e63ee, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Feb 25 06:17:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880487, encodeId=0fec188048eb0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Dec 24 13:17:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15928, encodeId=b233159288c, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=207, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:49:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573388, encodeId=532b15e338886, content=<a href='/topic/show?id=28f4125430b' target=_blank style='color:#2F92EE;'>#Nature Communications#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12543, encryptionId=28f4125430b, topicName=Nature Communications)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bea15872676, createdName=qindq, createdTime=Sat Feb 07 00:17:00 CST 2015, time=2015-02-07, status=1, ipAttribution=)]

相关资讯

医生必看:高通量基因测序产前筛查与诊断技术规范(试行)

2015年1月15日,卫计委妇幼司发布第一批产前诊断试点单位,同时发布了高通量基因测序产前筛查与诊断技术规范(试行)。与卫计委医政司发布的第一批试点相比,本次妇幼司发布的《通知》更为详细。这份高通量基因测序产前筛查与诊断技术规范(试行)规定了高通量基因测序产前筛查在临床上的适用范围、临床服务流程及临床质量控制。另外,还给出了高通量基因测序产前筛查与诊断知情同意书、临床申请单及临床报告单的参考模

CTG:基因突变或同饮酒吸烟“协作”增加胰腺炎风险

近日,一项发表于国际杂志Clinical and Translational Gastroenterology上的研究论文中,来自匹兹堡大学的研究人员通过研究发现,遗传突变、吸烟以及饮酒可相互作用共同增加个体患慢性胰腺炎的风险,相关研究或可揭示为何某些个体会患慢性胰腺炎,而单独的重度吸烟或重度饮酒者却并无疾病表现。 研究者David Whitcomb解释道,疾病的发病过程开始于急性胰腺炎,炎性症

Sci Signal:研究人员发现关键的促癌基因

TGF-β在癌症生物学中一直是个秘密,TGF-β如何既可以阻止癌细胞的形成,又如何刺激肿瘤积极生长。 现在,美国密歇根州综合癌症中心的研究人员已经发现一个关键基因,可以解释这种矛盾,提供潜在治疗靶标。 TGF-β是已知的肿瘤抑制因子,这意味着对于保持细胞正常生长是必要的。但在某些时候,它的功能会转换成肿瘤启动子,促进癌症发展与扩散。研究人员发现BUB1可作为参与调节TGF-β受体的一个关键基因

Nat Commun:新型乳腺癌基因的重大发现:BCL11A基因活跃在难治的三阴性乳腺癌中

一项新的研究确定了活跃在乳腺癌亚型中的基因。研究表明,过度活化的BCL11A基因驱动着三阴性乳腺癌发展和进程。 在人类细胞和老鼠上的研究为靶向治疗这种侵略性的肿瘤类型提供了新的途径。 有许多类型的乳腺癌对治疗的反应大有不同,也有不同的预测。大约五分之一的患者患有三阴性乳腺癌,这些癌症缺乏三种受体蛋白,而这些蛋白用于其他亚型的乳腺癌的应对激素疗法。近年来已经获得明显研究结果,大多数三阴性肿瘤有基

基因诊断行业监管的“小媳妇”现状

基因诊断,又称之为DNA诊断或分子诊断,是应用分子生物学方法,检测患者体内遗传物质结构或表达水平的变化,继而做出诊断的技术,它为疾病的预防、预测、诊断、治疗和疾病转归提供更为准确的信息。有报道称,2014年的全球体外诊断市场达到500亿美元,中国市场为60亿美元左右,其中基因诊断占比10%左右,并将以每年10%~20%的增长幅度连续增长,占体外诊断各类细分市场增长幅度之首。 然而,我国基因诊

Nature biotechnology:新发现染色质绝缘子或可用于人类基因治疗

                插入突变和遗传毒性通常代表造血系统肿瘤的恶化,同时也是实现基因治疗前景所面临的最大障碍。George Stamatoyannopoulos等人研究出一种能够识别作为绝缘子发挥功能的紧凑序列元件的方法,或对实现基因

Baidu
map
Baidu
map
Baidu
map